


RECELL™ Spray-On Skin™ Cells

Transform wound recovery with
skin cell suspension autograft

RECELL is a **groundbreaking, point-of-care, FDA premarket-approved** skin cell suspension autograft that helps clinicians achieve robust wound closure.¹ In **Europe, RECELL GO is CE marked under the European Union Medical Device Regulation.**

Designed for treatment of thermal burns, trauma, and surgical wounds, RECELL supports re-epithelialization, minimizes or eliminates the need for large autografts, and contributes to shorter hospital stays that reduce overall cost burden – returning patients back to activities of daily living, faster.^{1–9}



Providing point-of-care, multi-cell regenerative skin restoration with the RECELL System

The RECELL GO Autologous Cell Harvesting Device is CE marked under the European Union Medical Device Regulation. It uses a small split-thickness skin sample from the patient to prepare, at the point of care, an autologous skin cell suspension for application to a suitably prepared wound bed.

The resulting suspension contains a mixed population of skin cells, including keratinocytes, fibroblasts and melanocytes. According to the European Instructions for Use, the cells may be used for autologous application, as determined by the treating physician, for indications such as burns and other acute wounds, scars, chronic wounds and other dermal defects.

RECELL GO bears the CE 2797 marking. It should be used only by appropriately trained healthcare professionals and in accordance with the current Instructions for Use.



TREATING MORE WITH LESS

Caring for your patients means more than closing the wound. With RECELL, you can expedite the healing process with early point-of-care treatment of thermal burn wounds and full-thickness skin defects to provide the best possible outcomes for patients. RECELL is designed for donor sparing; significantly less donor skin is required with similar healing outcomes versus conventional autografting.



97.5%

LESS DONOR SKIN
FOR DEEP
PARTIAL-THICKNESS
(DPT) BURNS⁶

32%

LESS DONOR SKIN FOR FULL-
THICKNESS BURNS WHEN
USED IN COMBINATION WITH
AUTOGRAFT³

27%

LESS DONOR SKIN FOR FULL-
THICKNESS SKIN DEFECTS
WHEN USED IN COMBINATION
WITH AUTOGRAFT⁹

STEP-BY-STEP IMMEDIATE CELLULAR DELIVERY

Cost-effective point-of-care regenerative therapy
in a single procedure^{1,3}

1

Obtain

Harvest skin sample¹
1 cm² donor skin treats up to 80 cm²

2

Prepare

Isolate cells¹
Non-cultured, patient-derived cells

3

Deliver

RECELL treatment¹
Promotes epidermal regeneration

RECELL
Offers up to
80×
expansion

Clinical benefits of RECELL can lead to cost savings¹¹

Reduced donor skin requirements can result in fewer surgical procedures for definitive closure, decreased length of stay, and reduced resource use, translating to potential cost savings.^{7,8,11,12}

50%

UP TO 50% REDUCTION
IN DEFINITIVE CLOSURE
PROCEDURES¹¹


47%

UP TO 47% REDUCTION
IN LENGTH OF STAY
FOR BURNS <50% TBSA¹¹

39%

UP TO 39%
TOTAL COST
SAVINGS¹¹

How healing happens with RECELL



Clinicians harvest a thin sample of the patient’s own skin containing melanocytes, activated keratinocytes, and fibroblasts. The skin is processed in the device with the RECELL Enzyme™ to create an autologous skin cell suspension of Spray-On Skin Cells. When applied, the single cells generate re-epithelialization throughout the wound bed.^{1,10}

RECELL can be used alone or in combination with a skin graft. The multi-phenotype solution works in concert with the patient’s biology to accelerate healing, improve donor site aesthetic outcomes, and minimize or eliminate the need for traditional skin grafting.^{1,4-6}



Elevate standard of care with RECELL



RECELL’s impact to healthcare systems

Based on U.S. healthcare data

RECELL offers hospitals and health systems a powerful value proposition by accelerating wound closure and reducing donor skin harvesting.³⁻⁶

Patients with <30% TBSA deep partial-thickness burns spent 36% fewer days in the hospital when treated with RECELL than those treated with conventional autografts.²

SHORTEN LENGTH OF STAY BY

36%

Up to \$42K average savings per inpatient treated^{2,7-8}

Up to an additional 13 patients per bed annually^{2,7-8}

“From a national registry perspective, we are seeing significant hospital savings and a clearer understanding of how newer technologies like RECELL impact clinical decisions, length of stay, and patient outcomes.”

– Jeffrey E. Carter, MD, FACS, FABA



Real-World Confidence

30,000+

Patients treated worldwide

210+

Publications over 25+ years

16

Randomized controlled trials across burns and full-thickness wounds

Real-world outcomes: Patient cases

Today, healing means more than just wound closure.

[View Clinical Cases →](#)

References

1. Instructions for Use. RECELL® Autologous Cell Harvesting Device.
2. AVITA Medical Highlights Largest Real-World Analysis Demonstrating Reduced Hospital Stay with RECELL. Press release. June 9, 2025. Accessed September 29, 2025. <https://ir.avitamedical.com/news-releases/news-release-details/avita-medicalhighlights-largest-real-world-analysis>
3. Holmes JH IV, et al. Burns. 2019;45(4):772-782.
4. Navarro FA, et al. J Burn Care Rehabil. 2000;21(6):513-518.
5. Collins ML, et al. J Surg Res. 2024;302:925-935.
6. Holmes JH IV, et al. J Burn Care Res. 2018;39(5):694-702.
7. Carter JE, et al. Adv Ther. 2022;39(11):5191-5202.
8. Carson JS, et al. Burns. 2023;49(3):607-614.
9. Henry S, et al. J Trauma Acute Care Surg. 2024;96(1):85-93.
10. Bush KA, et al. Int Wound J. 2024;21(6):e14941.
11. Kowal S, et al. Adv Ther. 2019;36(7):1715-1729.
12. Foster K, et al. Presented at the American Burn Association Annual Meeting; April 2018.



IGIASI S.A.
Exclusive Representative of **RECELL** in Greece
19 Pigis Avenue
15127 Melissia, Greece
Tel: +30 210 8037950
Mobile: +30 698 3340000

IGIASI S.A. is the exclusive representative of RECELL in Greece, responsible for the commercial representation, distribution, and local support of RECELL products within the Greek market. RECELL is a medical device intended for use by appropriately trained healthcare professionals and in accordance with the applicable Instructions for Use, approved indications, and regulatory requirements. For information regarding product availability, clinical use, training, technical support, or other RECELL-related enquiries in Greece, please contact IGIASI S.A.